Cancer Neutron Capture Therapy

  • Yutaka Mishima

Table of contents

  1. Front Matter
    Pages i-xxvii
  2. Presidential Address

  3. Chemistry

    1. Macromolecular Species

      1. M. Frederick Hawthorne, Debra A. Feakes, Kenneth Shelly
        Pages 27-36
      2. Jacek Capala, Rolf F. Barth, Dianne M. Adams, Michael Q. Bailey, Albert H. Soloway, Jörgen Carlsson
        Pages 43-48
      3. Jörgen Carlsson, Lars Gedda, Christina Grönvik, Torbjörn Hartman, Annelie Lindström, Hans Lundqvist et al.
        Pages 49-56
      4. Robert R. Kane, Karin Drechsel, Young Soo Kim, Cynthia L. Beno, Christine S. Lee, Gabriel Mendez et al.
        Pages 57-65
      5. Liang Liu, Rolf F. Barth, Dianne M. Adams, Albert H. Soloway, Ralph A. Reisfeld
        Pages 67-73
      6. Hironobu Yanagië, Toshio Tomita, Hisao Kobayashi, Yuzo Fujii, Yoshiyuki Saegusa, Masazumi Eriguchi et al.
        Pages 75-79
    2. BPA and other Amino Acids

      1. Kazuo Yoshino, Yoshihiro Mori, Hidetake Kakihana, Hiroaki Takahashi, Yutaka Mishima, Masamitsu Ichihashi
        Pages 81-90
      2. Kazuo Yoshino, Nobuya Watanabe, Hiroaki Takahashi, Shinji Watanabe, Yoshihiro Mori, Masamitsu Ichihashi et al.
        Pages 91-97
      3. Iwona M. Wyzlic, John C. Beeson, Albert H. Soloway, Jinghong Yong, Rolf F. Barth
        Pages 105-110
      4. Yoshinori Kitaoka, Mitsue Kobayashi, Keizo Kawamoto, Tsuguhiro Morimoto, Mitsunori Kirihata, Itsuo Ichimoto
        Pages 111-114
      5. Kazuo Yoshino, Naoko Koike, Yuko Kuroda, Yoshihiro Mori, Masamitsu Ichihashi, Hidetake Kakihana et al.
        Pages 115-120
      6. Werner Tjarks, Jonas Malmquist, Lars Gedda, Stefan Sjöberg, Jörgen Carlsson
        Pages 121-126
    3. Carborane Related

      1. Jonas Malmquist, Jörgen Carlsson, Karin E. Markides, Patrik Pettersson, Pär Olsson, Kerstin Sunnerheim-Sjöberg et al.
        Pages 131-136
      2. Michiko Miura, Peggy L. Micca, Jason A. Donaldson, John C. Heinrichs, John A. Shelnutt, Gerald C. Finkel et al.
        Pages 137-141

About this book


There are many human cancers which actively synthesize specific characteristic proteins such as melanomas, thyroid cancer and squamous cell carcinoma. Many cancer researchers have of course tried to utilize this specific activity as a key for the selective treatment of cancers. In the past for example, the molecular hybrid compound of DOPA, a substrate of melanin, and nitrogen mustard N-oxide hydrochloride, a ctyotoxic anti-tumor drug, was synthesized as Melphalan and used to treat malignant melanoma. A major problem arose though in that it was soon found to be highly suppressive toward bone marrow and quite toxic while not being remarkably effective. Thus, malignant melanoma could not be cured by it. Such failure led us to develop a novel bimodal therapeutic system which includes the use of non-toxic potentially cytocidal chemicals which selectively accumulate within the cancer cells and which are converted by a controllable modality into an actively cytocidal element in situ. We can now non-surgically cure malignant melanoma and glioblastoma with our selective cancer treatment, neutron capture therapy (NCT); as can be found in this volume. Included are 124 papers on the latest breaking developments discussed at the Sixth International Symposium on NCT for Cancer held in Kobe during the late autumn of 1994.


Tumor bone carcinoma cells proteins

Editors and affiliations

  • Yutaka Mishima
    • 1
  1. 1.Mishima Institute for Dermatological ResearchKobeJapan

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag US 1996
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4757-9569-1
  • Online ISBN 978-1-4757-9567-7
  • About this book